Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18509855 | 1.00 | NAMPT (0.53) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL4372297 | 1.00 | NAMPT (0.53) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5087159 | 0.99 | NAMPT (0.52) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Bromide SCHEMBL11455325 | 0.99 | NAMPT (0.52) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20214289 | 0.99 | NAMPT (0.52) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL4953664 | 0.96 | NAMPT (0.49) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL4953654 | 0.96 | NAMPT (0.49) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| SCHEMBL5172065 | 0.89 | F2 (0.51) | NAMPTLMNAMMP2MMP9ALDH1A1 | |
| Glycyl Proline SCHEMBL28466633 | 0.86 | F2 (0.48) | LMNAMMP2MMP9ALDH1A1EPHX2 | |
| SCHEMBL28579566 | 0.86 | LMNA (0.48) | LMNAMMP2MMP9ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 648 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118256579-A | Preparation method of salmon skin DPP-IV inhibitory peptide | 集美大学 | 2024-06-28 | — | — | CN | claimed |
| CN-117886883-A | Thin-shell source peptide LTWR and preparation method and application thereof | 广西大学 | 2024-04-16 | — | — | CN | claimed |
| WO-2022180415-A1 | METHODS FOR PREDICTION OF SEVERITY AND RISK OF MORTALITY OF COVID-19 DISEASE AND PRE-SCREENING OF ACUTE SARS-COV-2 INFECTIONS | RAMGEN ZÁRTKÖRŰEN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG (HU) | 2022-09-01 | — | — | WO | claimed |
| EP-1221954-B1 | METHODS FOR IDENTIFYING INHIBITORS OF METHIONINE AMINOPEPTIDASES | UNIV SAINT LOUIS (US) | 2006-09-13 | — | — | EP | claimed |
| US-20030180828-A1 | Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor-and vasopeptidase inhibitor-associated angioedema | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-25 | — | — | US | claimed |
| US-20020137120-A1 | Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor-and vasopeptidase inhibitor-associated angioedema | VANDERBILT UNIVERSITY | 2002-09-26 | — | — | US | claimed |
| US-4191808-A | DIPEPTIDE CONTAINING PROLINE AND A PHOTOMETRICALLY DETECTABLE NITROANILINE, PHENYLAZOANILINE OR PHENYLAZONAPHTHYLAMINE GROUP | AJINOMOTO CO., INC. (JP) | 1980-03-04 | — | — | US | claimed |
| WO-2026103814-A1 | IRREVERSIBLE FAP INHIBITOR AND USE THEREOF | 南京科络思生物科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20260137820-A1 | TRIFUNCTIONAL COMPOUND AND USE THEREOF | PEKING UNIV (CN) | 2026-05-21 | — | — | US | disclosed |
| CN-117903243-B | Fructus cannabis extract polypeptide and application thereof | 清华大学深圳国际研究生院 | 2026-05-12 | — | — | CN | disclosed |
| US-20260014245-A1 | NEW MERS-COV VACCINE | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2026-01-15 | — | — | US | disclosed |
| CN-119661645-B | Sea cucumber protein heptapeptide with blood pressure and blood sugar reducing functions and application thereof | 山东栖蔓生物科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120025403-A | Novel ACE (angiotensin converting enzyme) inhibitory peptide with DPP-IV inhibitory activity and application thereof | 威海迪普森生物科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-1996038550-A1 | A NOVEL FORM OF DIPEPTIDYLPEPTIDASE IV (CD26) FOUND IN HUMAN SERUM, ANTIBODIES THERETO, AND USES THEREFOR | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1994028915-A1 | HIV RETROVIRUS INFECTION INHIBITOR CAPABLE OF INTERACTING WITH CD26 RECEPTOR | INSTITUT PASTEUR (FR) | 1994-12-22 | — | — | WO | disclosed |
| WO-1993007872-A1 | LYSOSOMAL ENZYME INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 1993-04-29 | — | — | WO | disclosed |
| US-RE33635-E | Enzymatic assay method | TOYO JOZO KABUSHIKI KAISHA (JP) | 1991-07-09 | — | — | US | disclosed |
| US-4681841-A | CONSUMING OXYGEN OR GENERATING A PIGMENT; MEASUREMENT BY AN OXYGEN ELECTRODE OR COLORIMETRIC ASSAY | TOYO JOZO KABUSHIKI KAISHA (JP) | 1987-07-21 | — | — | US | disclosed |
| US-4191808-A | DIPEPTIDE CONTAINING PROLINE AND A PHOTOMETRICALLY DETECTABLE NITROANILINE, PHENYLAZOANILINE OR PHENYLAZONAPHTHYLAMINE GROUP | AJINOMOTO CO., INC. (JP) | 1980-03-04 | — | — | US | disclosed |
| US-4119620-A | Novel dipeptide derivatives, salts thereof, and method of measuring enzyme activity | AJINOMOTO CO., INC. (JP) | 1978-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137820-A1 | TRIFUNCTIONAL COMPOUND AND USE THEREOF | STAU1, TIA1, GAR1 | NAMPT 3738/4885LMNA 730/4885MMP2 3791/4885 |
| US-20260014245-A1 | NEW MERS-COV VACCINE | TMPRSS4, DPP4, TMPRSS2 | NAMPT 1067/4885LMNA 1742/4885MMP2 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.